{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:58:59Z","timestamp":1791413939181,"version":"4.3.3"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Expectations"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prostate cancer is the second most common cancer worldwide, and there is no national prostate cancer screening programme in the United Kingdom. Men of African ancestry are twice as likely to be diagnosed as men of European ancestry and are diagnosed at a younger age. Despite this, Black men are under\u2010represented in seeking advice about prostate cancer symptoms, screening and genetic research. There is increasing research focused on targeted prostate cancer screening, using genetic testing to guide screening by identifying those at highest risk, but this could only be considered if people of all ethnicities would accept this approach. It is vital to diagnose prostate cancer early, when it is curable. We wanted to identify the barriers to engagement with prostate cancer genetic research to increase participation from those at highest risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted two community discussion groups, each attended by 30\u201335 Black men and their families. We conducted interviews with three Black community champions who have a lived experience of prostate cancer. Thematic analysis was performed on the transcripts. We used a participatory approach to develop our themes with members of the community, two of whom are co\u2010authors on this paper.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Themes were grouped as barriers or facilitators to engagement with prostate cancer genetic risk services. Barriers included GP reluctance to perform prostate\u2010specific antigen (PSA) testing, cultural inhibition around discussing prostate cancer and family history, fear of rectal examination, fear of cancer diagnosis and lack of trust in the healthcare system, no awareness about the role of genetics in prostate cancer risk assessment, negative connotations of genetic testing (e.g., genetic modification) and genetic data being used inappropriately. Facilitators were family and community support, the sharing of experiences, good communication with doctors, raised prostate cancer awareness, genetic risk assessment to guide the need for screening and facilitate early diagnosis, improving future outcomes for prostate cancer in the Black community through engaging with genetic research and assurance that there are regulations in place to protect genetic and personal data with guidance around when genetic results must be disclosed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Understanding barriers and facilitators can guide recommendations for health services to improve access and uptake within the Black community and improve representation in genetic research. Better representation will support improvements in cancer outcomes and understanding of the genetic risk of prostate cancer in the Black community.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient or Public Contribution<\/jats:title>\n                    <jats:p>We initially attended community prostate cancer awareness events to speak to members of the community. We established trusted and two\u2010way relationships with Black \u2018community champions\u2019 who lead support groups in the Black community and often have a lived experience of prostate cancer. We were invited to attend their support groups to deliver awareness talks and address concerns about prostate cancer risk and screening. We then conducted discussion groups and collected data. Our analysis was conducted in partnership with our community champions. Our findings are described in this paper, with their co\u2010authorship. We have also disseminated our findings in a co\u2010produced newsletter to feed back our findings to the community members, who gave us their time. We have also shared information at a stakeholder day, attended by 65 individuals from the community, where we also planned future work. We have reimbursed participants for their time, which is in line with NIHR guidance. As described above, patient and public involvement has been the guiding principle throughout this project.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hex.70282","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:50:24Z","timestamp":1745974224000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding Barriers to Engagement With a Prostate Cancer Research and Genetic Risk Service Among UK Men of Black African or Black Caribbean Ancestry"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7961-0420","authenticated-orcid":false,"given":"Hall","family":"Rose","sequence":"first","affiliation":[{"name":"The Institute of Cancer Research London UK"},{"name":"The Royal Marsden NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hainsworth","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research London UK"},{"name":"The Royal Marsden NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Thompson","sequence":"additional","affiliation":[{"name":"Cancer Don't Let it Win London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saran","family":"Green","sequence":"additional","affiliation":[{"name":"The Patient and Public Involvement Cancer Research Group for Diverse Backgrounds London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McGrowder","family":"Eva","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Denzil","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research London UK"},{"name":"The Royal Marsden NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeles","family":"Rosalind","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research London UK"},{"name":"The Royal Marsden NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Bancroft","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research London UK"},{"name":"The Royal Marsden NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040760"},{"key":"e_1_2_11_3_1","unstructured":"UK CR \u201cProstate Cancer Statistics 2023 \u201d accessed August 22 2023 https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer."},{"key":"e_1_2_11_4_1","unstructured":"(NICE) NIfHaCE \u201cWhat Should I Advise About Screening for Prostate Cancer? \u201d accessed July 3 2023 https:\/\/cks.nice.org.uk\/topics\/prostate-cancer\/diagnosis\/screening-for-prostate-cancer\/."},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb2000250"},{"key":"e_1_2_11_6_1","unstructured":"Excellence NIfHaC \u201cHow Should I Assess a Person With Suspected Prostate Cancer? \u201d accessed February 25 2025 https:\/\/cks.nice.org.uk\/topics\/prostate-cancer\/diagnosis\/assessment\/."},{"key":"e_1_2_11_7_1","unstructured":"NICE Guideline \u201cSuspected Cancer: Recognition and Referral \u201d accessed February 5 2024 https:\/\/www.nice.org.uk\/guidance\/ng12\/chapter\/Recommendations-organised-by-site-of-cancer#urological-cancers."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25471"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.289"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23247"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40142-021-00202-5"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01534-4"},{"key":"e_1_2_11_13_1","unstructured":"UK PC \u201cWe Now Recommend All Black Men Over 45 Speak to Their GP About a PSA Blood Test \u201d accessed January 2025 https:\/\/prostatecanceruk.org\/about-us\/news-and-views\/2023\/01\/black-men-over-45-speak-to-their-gp-about-a-psa-blood-test#:~:text=Priority%20Message%3A%20Because%20Black%20men a%20GP%20from%20any%20age."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2009.09.012"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/538161a"},{"key":"e_1_2_11_16_1","unstructured":"Government UK.Population of England and Wales\u2014Ethnicity Facts and Figures.2022."},{"key":"e_1_2_11_17_1","unstructured":"R.Thompson \u201cHear Me Now\u2014The Uncomfortable Reality of Prostate Cancer in Black African\u2010Carribean Men \u201d accessed June 14 2024 https:\/\/issuu.com\/bmecancer.com\/docs\/hearme_now\/1."},{"key":"e_1_2_11_18_1","unstructured":"Nottingham GAUatUo.Familial Cancer Risk in People From Ethnic Minorities.2012."},{"key":"e_1_2_11_19_1","unstructured":"NIHR \u201cNIHR Co\u2010Production in Action (Number One) \u201d accessed July 4 2024 https:\/\/www.learningforinvolvement.org.uk\/content\/resource\/nihr-co-production-in-action-number-one\/#:~:text=Key%20Principles -From%20the%20Guidance&text=including%20all%20perspectives%20and%20skills everybody%20benefits%20from%20working%20together."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.12821"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-017-0071-1"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0620-8"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13215"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2015-004839"},{"key":"e_1_2_11_25_1","volume-title":"Thematic Analysis\u2014a Practical Guide","author":"Ba C.","year":"2022"},{"key":"e_1_2_11_26_1","unstructured":"Y. G.LincolnandE. G.Lincoln Guba's Evaluative Criteria 1985.http:\/\/www.qualres.org\/HomeLinc-3684.html."},{"key":"e_1_2_11_27_1","unstructured":"Care DoHaS \u201cCode on Genetic Testing and Insurance: 3\u2010Year Review 2022 \u201d accessed March 3 2025 https:\/\/www.gov.uk\/government\/publications\/code-on-genetic-testing-and-insurance-3-year-review-2022\/code-on-genetic-testing-and-insurance-3-year-review-2022."},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/her\/cyy001"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pon.2043"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1557988316637879"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2017.26.18.S14"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-017-1167-x"},{"key":"e_1_2_11_33_1","unstructured":"Health Do. Improving Outcomes: A Strategy for Cancer. Second Annual Report 2012 https:\/\/assets.publishing.service.gov.uk\/media\/5a7cb45de5274a2f304ef94a\/IOSC-Second-Annual-Report-Final.pdf."},{"key":"e_1_2_11_34_1","unstructured":"Parliament U. Prostate Cancer. Volume 458.2007."},{"key":"e_1_2_11_35_1","unstructured":"Find a Support Group cited June 2024 https:\/\/prostatecanceruk.org\/prostate-information-and-support\/get-support\/support-groups."}],"updated-by":[{"DOI":"10.1111\/hex.70341","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000}}],"container-title":["Health Expectations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hex.70282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T09:43:14Z","timestamp":1763113394000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hex.70282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/hex.70282"],"URL":"https:\/\/doi.org\/10.1111\/hex.70282","archive":["Portico"],"relation":{},"ISSN":["1369-6513","1369-7625"],"issn-type":[{"value":"1369-6513","type":"print"},{"value":"1369-7625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"2024-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70282"}}